BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM) | 10-Q: FY2025 Q3 EPS: USD -1.64

LB filings
2025.06.16 20:36
portai
I'm PortAI, I can summarize articles.

EPS: As of FY2025 Q3, the actual value is USD -1.64.

Segment Revenue

  • Research, Development, and Clinical Trial Costs: For the three-month period ended April 30, 2025, total research, development, and clinical trial costs amounted to $4,810,196, compared to $7,657,632 for the same period in 2024. For the nine-month period ended April 30, 2025, these costs were $14,160,314, down from $22,772,344 in 2024.

Operational Metrics

  • Net Loss: The net loss for the three-month period ended April 30, 2025, was $6,224,929, compared to a net income of $1,692,242 for the same period in 2024. For the nine-month period ended April 30, 2025, the net loss was $18,392,033, compared to $3,682,796 in 2024.
  • Operating Loss: The operating loss for the three-month period ended April 30, 2025, was $6,328,255, compared to $9,229,648 in 2024. For the nine-month period ended April 30, 2025, the operating loss was $18,650,530, compared to $27,562,122 in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities for the nine-month period ended April 30, 2025, was $20,038,075, compared to $20,090,398 for the same period in 2024.
  • Financing Activities: Cash gained from financing activities for the nine-month period ended April 30, 2025, was $31,891,239, compared to nil for the same period in 2024.

Unique Metrics

  • Change in Fair Value of Warrant Liability: For the three-month period ended April 30, 2025, the change in fair value of the warrant liability was $175,826, compared to $10,945,672 in 2024. For the nine-month period ended April 30, 2025, it was $366,024, compared to $23,660,003 in 2024.

Future Outlook and Strategy

  • Core Business Focus: The company is advancing its Bria-IMT™ targeted immunotherapy in a pivotal Phase 3 study in metastatic breast cancer, which is under Fast Track Designation by the U.S. FDA. Completion of this study could lead to full approval of Bria-IMT™ plus an immune checkpoint inhibitor.
  • Non-Core Business: BriaCell is conducting a Phase 1⁄2 study to evaluate Bria-OTS™, a personalized next-generation immunotherapy, in metastatic breast cancer and other cancers. This study investigates Bria-OTS™ alone and in combination with an immune checkpoint inhibitor.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.